There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Abstract
Objective: Animal studies suggest the involvement of N-methyl-D-aspartate (NMDA) receptors
as a novel mechanism of methylphenidate (MPH). We investigated the association between
the NMDA subunit 2B gene (GRIN2B) and the treatment response to MPH in attention-deficit/hyperactivity
disorder (ADHD).
Methods: A total of 75 ADHD patients aged 6–17 years completed the pre- and post-treatment
assessments after 6 months of MPH administration. Treatment response was defined by
changes in scores on the parent version of the ADHD-IV Rating Scale (ADHD-RS), clinician-rated
Clinical Global Impression – Improvement (CGI-I), and Continuous Performance Test
(CPT). The association of the GRIN2B rs2284411 polymorphism with treatment response
was analyzed using a series of logistic regression analyses.
Results: There was a significant genotype effect in treatment response as assessed
by ADHD-RS inattention (p = 0.009), hyperactivity-impulsivity (p = 0.028), and total
(p = 0.023) scores, and in the CGI-I scores (p = 0.009) after adjusting for age, sex,
IQ, baseline Clinical Global Impression – Severity score, baseline ADHD-RS total score,
and final MPH dose. When using a stricter standard, the C/C genotype was associated
with greater improvement in ADHD-RS inattention and CGI-I (p = 0.026), ADHD-RS hyperactivity-impulsivity
and CGI-I (p = 0.017), and ADHD-RS total and CGI-I (p = 0.048) scores. Improvement
in response time variability scores of the CPT differed between GRIN2B genotypes (p
< 0.001).
Conclusions: The results suggest that the GRINB rs2284411 genotype may be an important
predictor of MPH response in ADHD. Further placebo-controlled randomized studies with
larger samples are required.